Financial Data and Key Metrics Changes - In 2025, the company achieved consolidated NOI growth of 31.3% and reduced leverage by over three turns, with no debt maturities until 2028 [6][12] - Total revenue for the fourth quarter was $379.6 million, with Adjusted EBITDAre of $72.4 million and Normalized FFO of $21.8 million or $0.09 per share [8][22] - Full year Adjusted EBITDAre was $284 million, at the high end of guidance [22] Business Line Data and Key Metrics Changes - The SHOP NOI for the full year was $139.3 million, driven by a same-property occupancy increase of 90 basis points year-over-year to 82.4% and an average monthly rate increase of 5.8% [8][16] - Medical office and life science NOI was $108.1 million, just above the midpoint of guidance, while triple net lease senior living community and wellness center NOI was $31.1 million, exceeding guidance [22] Market Data and Key Metrics Changes - Consolidated occupancy in the medical office and life science portfolio increased by 460 basis points sequentially to 91.2% [11] - Same-property Cash Basis NOI increased 3.8% year-over-year, with margins improving 100 basis points to 59.6% [11] Company Strategy and Development Direction - The company aims to continue unlocking value through operational improvements and has identified approximately 15 locations for potential reopening of wings, which could add around 500 units to the portfolio [27] - Future dispositions will be opportunistic, focusing on reducing leverage or redeploying into accretive initiatives [14][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2026 outlook, supported by a robust demand for SHOP communities and a favorable industry outlook [10][14] - The company anticipates strong improvements in SHOP segment performance and reduced debt, driving free cash flow growth [22] Other Important Information - The company completed the wind down of AlerisLife, transitioning 116 communities to seven operators and completed renovations at over 30 communities [5][6] - The company expects recurring capital expenditures for 2026 to range from $100 million to $115 million, representing an over 18% decrease compared to 2025 [18] Q&A Session Summary Question: What is the go-forward strategy and opportunities for reopening wings? - The main strategy focuses on growing performance through operations, with potential for 500 units from reopening wings at identified locations [26][27] Question: Will external investments focus on renovations or acquisitions? - Renovations are prioritized for better risk-adjusted returns, but acquisitions are not ruled out for the future [28][29] Question: What drove the fourth quarter margin improvement? - The improvement was due to a combination of reduced transition disruptions and core operational gains [30] Question: What are the trends for January and February? - January showed promising results in line with expectations, with rent escalators around 4%-6% [32][33] Question: How does the company view NOI growth for the coming quarters? - NOI growth is expected to be back half of the year weighted due to ongoing transitions [38] Question: What are the prospects for renewing leases in the medical office and life science segment? - There are promising outlooks for re-leasing, particularly in the Fremont building, which is in a strong R&D market [44] Question: What implications does the momentum have on dividends? - The board will consider dividends, but there are no immediate priorities for addressing them [52]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $382.7 million, a 3% increase year over year [7] - Adjusted EBITDAre was $73.6 million, up 7% year over year [7] - Normalized FFO increased 172% year over year to $18.6 million, or $0.08 per share [7] Business Line Data and Key Metrics Changes - Same property SHOP NOI increased by 18.5% year over year to $37.4 million [8] - Average monthly rate in the SHOP sector increased by 5.4% year over year, with occupancy rising by 160 basis points to 80.6% [8] - SHOP revenue increased by 6.2% year over year [8] - Medical office and life science portfolio had same property occupancy at 89.9%, down 10 basis points from Q1 [10] Market Data and Key Metrics Changes - The active leasing pipeline in the medical office and life science portfolio includes 691,000 square feet, with 246,000 square feet being new absorption [10] - Weighted average rents for new and renewal leasing activity were 11.5% higher than prior rents [10] Company Strategy and Development Direction - The company is focused on deleveraging its balance sheet through asset sales and refinancing at attractive rates [7] - DHC sold two unencumbered properties for a total of $16.4 million and three additional properties in July for $8.8 million [11] - The company aims to enhance its portfolio with a higher concentration of SHOP assets and stable cash flows from medical office and life science properties [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued recovery of the SHOP segment and the overall positive outlook for the business [10] - The company expects to meet its 2026 debt maturity and anticipates a reduction in leverage towards a target of 6.5 to 7.5 times [20] Other Important Information - The company reduced its 2025 CapEx guidance to $140 million to $160 million, a $10 million reduction from prior guidance [17] - As of July, the company had approximately $292 million in liquidity, including $142 million in unrestricted cash [18] Q&A Session Summary Question: Any notable one-time issues in Q2 2025? - Management indicated that the majority of the NOI benefit came in Q1, with a minor benefit in Q2 from PLGL insurance, approximately $1 million [24][38] Question: CapEx guidance change details? - The change was due to dispositions and a comparison of actual year-to-date spend against the budget [27] Question: Disposition pipeline and future sales? - Management confirmed a mix of assets under PSA and LOI, with additional properties expected to close by year-end or into 2026 [28][30] Question: Performance of Five Star assets compared to others? - Five Star properties have shown improvements due to operational enhancements and capital investments, leading to better performance [31][34] Question: Occupancy targets and growth expectations? - Management expects gradual occupancy growth towards the year-end target of over 82%, influenced by seasonal trends and ongoing dispositions [35]